Preservation of Myocardial Beta-adrenergic Receptor Signaling Delays the Development of Heart Failure After Myocardial Infarction

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2000 Apr 26

PMID 10779554

Citations 66

Authors

D C White

J A Hata

A S Shah

D D Glower

R J Lefkowitz

W J Koch

Affiliations

Soon will be listed here.

Abstract

When the heart fails, there is often a constellation of biochemical alterations of the beta-adrenergic receptor (betaAR) signaling system, leading to the loss of cardiac inotropic reserve. betaAR down-regulation and functional uncoupling are mediated through enhanced activity of the betaAR kinase (betaARK1), the expression of which is increased in ischemic and failing myocardium. These changes are widely viewed as representing an adaptive mechanism, which protects the heart against chronic activation. In this study, we demonstrate, using in vivo intracoronary adenoviral-mediated gene delivery of a peptide inhibitor of betaARK1 (betaARKct), that the desensitization and down-regulation of betaARs seen in the failing heart may actually be maladaptive. In a rabbit model of heart failure induced by myocardial infarction, which recapitulates the biochemical betaAR abnormalities seen in human heart failure, delivery of the betaARKct transgene at the time of myocardial infarction prevents the rise in betaARK1 activity and expression and thereby maintains betaAR density and signaling at normal levels. Rather than leading to deleterious effects, cardiac function is improved, and the development of heart failure is delayed. These results appear to challenge the notion that dampening of betaAR signaling in the failing heart is protective, and they may lead to novel therapeutic strategies to treat heart disease via inhibition of betaARK1 and preservation of myocardial betaAR function.

Citing Articles

Canonical or non-canonical, all aspects of G protein-coupled receptor kinase 2 in heart failure.

Kaplan A, El-Samadi L, Zahreddine R, Amin G, Booz G, Zouein F Acta Physiol (Oxf). 2025; 241(3):e70010.

PMID: 39960030 PMC: 11831727. DOI: 10.1111/apha.70010.

Innate and adaptive immune system consequences of post-traumatic stress disorder.

Lauten T, Natour T, Case A Auton Neurosci. 2024; 252:103159.

PMID: 38428324 PMC: 11494466. DOI: 10.1016/j.autneu.2024.103159.

Myocardial GRK2 Reduces Fatty Acid Metabolism and β-Adrenergic Receptor-Mediated Mitochondrial Responses.

Zhai R, Varner E, Rao A, Karhadkar S, Di Carlo A, Snyder N Int J Mol Sci. 2022; 23(5).

PMID: 35269919 PMC: 8911442. DOI: 10.3390/ijms23052777.

Ophiopogonin D Increases SERCA2a Interaction with Phospholamban by Promoting CYP2J3 Upregulation.

Wang J, You W, Wang N, Zhou W, Ge Y, Ma Z Oxid Med Cell Longev. 2021; 2020:8857906.

PMID: 33488937 PMC: 7790559. DOI: 10.1155/2020/8857906.

Adrenergic Signaling in Circadian Control of Immunity.

Leach S, Suzuki K Front Immunol. 2020; 11:1235.

PMID: 32714319 PMC: 7344327. DOI: 10.3389/fimmu.2020.01235.

References

Inglese J, Freedman N, Koch W, Lefkowitz R . Structure and mechanism of the G protein-coupled receptor kinases. J Biol Chem. 1993; 268(32):23735-8. View

Bristow M, Ginsburg R, Minobe W, Cubicciotti R, Sageman W, Lurie K . Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982; 307(4):205-11. DOI: 10.1056/NEJM198207223070401. View

Urasawa K, Yoshida I, Takagi C, Onozuka H, Mikami T, Kawaguchi H . Enhanced expression of beta-adrenergic receptor kinase 1 in the hearts of cardiomyopathic Syrian hamsters, BIO53.58. Biochem Biophys Res Commun. 1996; 219(1):26-30. DOI: 10.1006/bbrc.1996.0175. View

Bristow M, Lowes B . Low-dose inotropic therapy for ambulatory heart failure. Coron Artery Dis. 1994; 5(2):112-8. DOI: 10.1097/00019501-199402000-00004. View

Leimbach Jr W, Wallin B, Victor R, Aylward P, Sundlof G, Mark A . Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation. 1986; 73(5):913-9. DOI: 10.1161/01.cir.73.5.913. View

Lefkowitz R, Rockman H, Koch W . Catecholamines, cardiac beta-adrenergic receptors, and heart failure. Circulation. 2000; 101(14):1634-7. DOI: 10.1161/01.cir.101.14.1634. View

Bristow M . Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol. 1997; 80(11A):26L-40L. DOI: 10.1016/s0002-9149(97)00846-1. View

Luttrell L, Ferguson S, Daaka Y, Miller W, Maudsley S, Della Rocca G . Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science. 1999; 283(5402):655-61. DOI: 10.1126/science.283.5402.655. View

Maurice J, Shah A, Kypson A, Hata J, White D, Glower D . Molecular beta-adrenergic signaling abnormalities in failing rabbit hearts after infarction. Am J Physiol. 1999; 276(6):H1853-60. DOI: 10.1152/ajpheart.1999.276.6.H1853. View

10.

Hehir K, Armentano D, Cardoza L, Choquette T, Berthelette P, White G . Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence. J Virol. 1996; 70(12):8459-67. PMC: 190936. DOI: 10.1128/JVI.70.12.8459-8467.1996. View

11.

Packer M, Bristow M, Cohn J, Colucci W, Fowler M, Gilbert E . The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996; 334(21):1349-55. DOI: 10.1056/NEJM199605233342101. View

12.

Ungerer M, Bohm M, Elce J, Erdmann E, Lohse M . Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation. 1993; 87(2):454-63. DOI: 10.1161/01.cir.87.2.454. View

13.

Iaccarino G, Tomhave E, Lefkowitz R, Koch W . Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade. Circulation. 1998; 98(17):1783-9. DOI: 10.1161/01.cir.98.17.1783. View

14.

Bristow M, Minobe W, Raynolds M, Port J, Rasmussen R, Ray P . Reduced beta 1 receptor messenger RNA abundance in the failing human heart. J Clin Invest. 1993; 92(6):2737-45. PMC: 288472. DOI: 10.1172/JCI116891. View

15.

Brodde O . Beta-adrenoceptors in cardiac disease. Pharmacol Ther. 1993; 60(3):405-30. DOI: 10.1016/0163-7258(93)90030-h. View

16.

Colucci W, Alexander R, Williams G, Rude R, HOLMAN B, Konstam M . Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. N Engl J Med. 1981; 305(4):185-90. DOI: 10.1056/NEJM198107233050402. View

17.

Maurice J, Hata J, Shah A, White D, McDonald P, Dolber P . Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary beta2-adrenergic receptor gene delivery. J Clin Invest. 1999; 104(1):21-9. PMC: 408402. DOI: 10.1172/JCI6026. View

18.

Rockman H, Chien K, Choi D, Iaccarino G, Hunter J, ROSS Jr J . Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci U S A. 1998; 95(12):7000-5. PMC: 22717. DOI: 10.1073/pnas.95.12.7000. View

19.

Koch W, Inglese J, Stone W, Lefkowitz R . The binding site for the beta gamma subunits of heterotrimeric G proteins on the beta-adrenergic receptor kinase. J Biol Chem. 1993; 268(11):8256-60. View

20.

Ungerer M, Kessebohm K, Kronsbein K, Lohse M, Richardt G . Activation of beta-adrenergic receptor kinase during myocardial ischemia. Circ Res. 1996; 79(3):455-60. DOI: 10.1161/01.res.79.3.455. View